BCMA-CD38 CAR-T cells

BCMA-CD38 CAR-T cells are a type of chimeric antigen receptor (CAR) T cell therapy engineered to target both B-cell maturation antigen (BCMA) and CD38 on the surface of malignant plasma cells. These autologous or allogeneic T cells are genetically modified to express synthetic receptors that recognize and bind to both BCMA and CD38 antigens, which are commonly overexpressed in multiple myeloma and other hematologic malignancies. Upon intravenous administration, these dual-targeting CAR-T cells induce selective cytotoxicity against tumor cells expressing either or both antigens by activating the patient's immune response. This multi-specific approach is designed to enhance efficacy by reducing the risk of antigen escape—a common mechanism of resistance in single-target therapies—and may improve outcomes for patients with relapsed or refractory multiple myeloma[1][2][4]. Preclinical studies have demonstrated improved immune activation, increased cytotoxicity, enhanced expansion under repetitive tumor challenges, and mitigation of inhibitory effects from soluble BCMA compared to mono- or dual-specific constructs[2]. Clinical trials have evaluated combinations using humanized anti-BCMA with murine anti-CD38 targeting domains[4].

Other names

anti-CD38/BCMA CAR T lymphocytesmultivalent BCMA/CD38 CAR-T cells